Novocure falls as CEO Asaf Danziger to step down

NovoCure

03/09/2024 14:46

** Shares of cancer therapy developer Novocure  NVCR.O  down
~2.2% at $19.02 
    ** Company says CEO Asaf Danziger will retire at year end
and finance chief Ashley Cordova, will succeed him as the next
CEO
    ** Asaf Danziger has served as NVCR's CEO since 2002
    ** Up to last close, stock up 30.2% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))